EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App NL‐G‐F KI mice

Yo Tsuda, Yuta Madokoro, Kengo Suzuki, Takuya Ooba, Toyohiro Sato, Yuto Uchida, Itsumi Nagai-Arakawa, Takashi Saito, Hideaki Hara, Hideki Hida, Noriyuki Matsukawa

Alzheimer's & Dementia · 2026-06 · 22 (6)

DOI: 10.1002/alz.71531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 03.06.2026. Verfasst von Yo Tsuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Amyloid beta-Protein Precursor, Hippocampus, Memory Disorders, Neuropeptides. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Dainippon Sumitomo Pharma, Eisai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Whether cholinergic activity in the septohippocampal network affects cognitive dysfunction via hippocampal cholinergic neurostimulating peptide (HCNP) in Alzheimer's pathogenesis remains unclear. METHODS An Alzheimer's pathogenesis by mutation in amyloid‐beta precursor protein gene ( App NL‐G‐F ) knock‐in (KI) and HCNP precursor protein conditional knockout (HCNP‐pp cKO) mouse model was generated, exhibiting both cholinergic dysfunction and amyloid pathogenesis. Theta power‐related cholinergic function and long‐term potentiation (LTP) were evaluated in App NL‐G‐F KI/HCNP‐pp cKO mice. Molecules associated with the cholinergic/glutamatergic neurons, amyloid beta (Aβ), and inflammation were examined. RESULTS Reduced HCNP levels enhanced cognitive impairment, inhibiting theta power and LTP, although without accompanying pathological changes or inflammation. Decreased N ‐methyl‐D‐aspartate receptor subunit 2A (NR2A), choline acetyltransferase (ChAT), and Vesicular acetylcholine transporter (VAChT) levels were observed in the hippocampus and ChAT in the medial septal nucleus (MSN) of App NL‐G‐F KI/HCNP‐pp cKO mice. DISCUSSION Cholinergic dysfunction in HCNP‐pp cKO mice exacerbates cognitive dysfunction in App NL‐G‐F KI mice. The obtained mouse models are expected to be used to investigate cholinergic dysfunction and amyloid pathogenesis in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-Protein PrecursorHippocampusMemory DisordersNeuropeptidesAlzheimer DiseaseAnimalsMiceDisease Models, AnimalMice, KnockoutMice, TransgenicLong-Term PotentiationMale

Stichwörter der Autor:innen

Alzheimer's diseaseAppNL‐G‐F knock‐incholinergic dysfunctionhippocampal cholinergic neurostimulating peptidehippocampal cholinergic neurostimulating peptide precursor protein

Substanzen

Amyloid beta-Protein Precursorhippocampal cholinergic neurostimulating peptideNeuropeptides

Autor:innen und Institutionen

  • Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Gifu, Japan.
  • Department of Neurocognitive Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Neurophysiology and Brain Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Dainippon Sumitomo Pharma
  • Eisai
  • Daiichi-Sankyo
  • Otsuka Pharmaceutical

Zitieren

APA

Tsuda, Y., Madokoro, Y., Suzuki, K., Ooba, T., Sato, T., Uchida, Y., Nagai-Arakawa, I., Saito, T., Hara, H., Hida, H., & Matsukawa, N. (2026). Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App NL‐G‐F KI mice. Alzheimer's & Dementia, 22(6). https://doi.org/10.1002/alz.71531

Vancouver

Tsuda Y, Madokoro Y, Suzuki K, Ooba T, Sato T, Uchida Y, et al. Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App NL‐G‐F KI mice. Alzheimer's & Dementia. 2026;22(6). doi:10.1002/alz.71531

BibTeX
@article{Tsuda2026,
  author = {Tsuda, Yo and Madokoro, Yuta and Suzuki, Kengo and Ooba, Takuya and Sato, Toyohiro and Uchida, Yuto and Nagai-Arakawa, Itsumi and Saito, Takashi and Hara, Hideaki and Hida, Hideki and Matsukawa, Noriyuki},
  title = {Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App NL‐G‐F KI mice},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {6},
  doi = {10.1002/alz.71531}
}
Kostenlos starten →